Masso Torrence Wealth Management Inc. Corvus Pharmaceuticals, Inc. Transaction History
Masso Torrence Wealth Management Inc.
- $177 Million
- Q3 2024
A detailed history of Masso Torrence Wealth Management Inc. transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Masso Torrence Wealth Management Inc. holds 10,000 shares of CRVS stock, worth $67,900. This represents 0.03% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$67,900
Previous $18,000
188.89%
% of portfolio
0.03%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding CRVS
# of Institutions
73Shares Held
30.4MCall Options Held
1.06MPut Options Held
84.3K-
Orbimed Advisors LLC San Diego, CA6.94MShares$47.1 Million0.86% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.56MShares$37.8 Million0.08% of portfolio
-
Samlyn Capital, LLC New York, NY4.53MShares$30.8 Million0.39% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$22.2 Million10.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$16.4 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $316M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...